N. Anthony Coles - Jul 1, 2024 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Director
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Jul 1, 2024
Transactions value $
-$942,035
Form type
4
Date filed
7/3/2024, 04:05 PM
Previous filing
Jun 7, 2024
Next filing
Aug 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $87.5K +25K +96.42% $3.50* 50.9K Jul 1, 2024 Direct F1, F2
transaction CERE Common Stock Sale -$1.03M -25K -49.09% $41.18 25.9K Jul 1, 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -25K -1.14% $0.00 2.18M Jul 1, 2024 Common Stock 25K $3.50 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person.
F2 This number includes 10,290 unvested Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. These RSUs shall vest upon the earlier of: (i) June 5, 2025, or (ii) the 2025 annual meeting of stockholders of the Company.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $40.85 to $41.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The option is fully vested and exercisable.